LivingGLP1
Study S000566

Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT01761318
Acronym
MAGNA VICTORIA
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
50
Start
2013-11
Primary completion
2016-03
Lead sponsor
Leiden University Medical Center
Conditions
Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver
Interventions
DRUG:Liraglutide; DRUG:Liraglutide - Placebo
Results posted
FALSE
Secondary identifiers
EUDRACT_NUMBER:2012-001623-12

Registered primary outcomes

  • Stroke volume [0 and 26 weeks]
  • Ejection Fraction [0 and 26 weeks]
  • Cardiac output [0 and 26 weeks]
  • Cardiac index [0 and 26 weeks]
  • Peak ejection rate [0 and 26 weeks]
  • Early peak filling rate [0 and 26 weeks]
  • Early deceleration peak [0 and 26 weeks]
  • Atrial peak filling rate [0 and 26 weeks]
  • Early deceleration peak / Atrial peak filling rate (E/A ratio) [0 and 26 weeks]
  • Peak mitral annulus longitudinal motion [0 and 26 weeks]
  • Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion) [0 and 26 weeks]

Linked records (17)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0010237Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
Natale P, The Cochrane database of systematic reviews
2025Systematic reviewPMID 39963952DOIcites ClinicalTrials.gov:NCT01761318; registry reference DERIVED:39963952
R0009172Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.
Hoekx CA, Experimental physiology
2024OtherPMID 38965822DOIcites ClinicalTrials.gov:NCT01761318
R0011702The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial.
Dekkers IA, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
2021Randomized trialPMID 33293204DOIcites ClinicalTrials.gov:NCT01761318; registry reference DERIVED:33293204
R0020707Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.
van Eyk HJ, Nutrition, metabolism, and cardiovascular diseases : NMCD
2020Randomized trialPMID 32127340DOIcites ClinicalTrials.gov:NCT01761318; registry reference DERIVED:32127340
R0022308Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
Bizino MB, Diabetologia
2020Randomized trialPMID 31690988DOIcites ClinicalTrials.gov:NCT01761318; registry reference DERIVED:31690988
R0021188Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.
van Eyk HJ, Scientific reports
2019Randomized trialPMID 31292457DOIcites ClinicalTrials.gov:NCT01761318; registry reference DERIVED:31292457
R0024672Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
Bizino MB, Cardiovascular diabetology
2019Randomized trialPMID 31039778DOIcites ClinicalTrials.gov:NCT01761318; registry reference DERIVED:31039778
R0023385Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Jendle J, Diabetes, obesity & metabolism
2009Randomized trialPMID 19930006DOIregistry reference BACKGROUND:19930006
R0025460Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Timmers L, Journal of the American College of Cardiology
2009Randomized trialPMID 19195607DOIregistry reference BACKGROUND:19195607
R0026073Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Marre M, Diabetic medicine : a journal of the British Diabetic Association
2009Randomized trialPMID 19317822DOIregistry reference BACKGROUND:19317822
R0027526Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Garber A, Lancet (London, England)
2009Randomized trialPMID 18819705DOIregistry reference BACKGROUND:18819705
R0056815The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart.
Ossum A, Pharmacological research
2009PreclinicalPMID 19540343DOIregistry reference BACKGROUND:19540343
R0024418Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart.
Sonne DP, Regulatory peptides
2008PreclinicalPMID 17976835DOIregistry reference BACKGROUND:17976835
R0027817Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Ban K, Circulation
2008PreclinicalPMID 18427132DOIregistry reference BACKGROUND:18427132
R0027891GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.
Green BD, Archives of biochemistry and biophysics
2008PreclinicalPMID 18708025DOIregistry reference BACKGROUND:18708025
R0021373Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
Ding X, Hepatology (Baltimore, Md.)
2006PreclinicalPMID 16374859DOIregistry reference BACKGROUND:16374859
R0025957Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L, Diabetes, obesity & metabolism
2006Randomized trialPMID 16776751DOIregistry reference BACKGROUND:16776751